Helping patients save on biomarker testing*
Click on the appropriate box below to learn more about financial support options associated with comprehensive biomarker testing, including KRAS G12C testing for patients diagnosed with stage IV metastatic non-small cell lung cancer (NSCLC)*
KRAS= Kirsten Rat Sarcoma
*Program limitations apply, please see terms and conditions including limits on individual program coverages. Programs valid for testing performed through December 31, 2023.